La Jolla Pharmaceuticals About
La Jolla Pharmaceuticals La Jolla Pharmaceutical Company is a
biotechnology company leading the development of therapeutics for antibody-mediated
autoimmune
diseases afflicting several million people in the United States and Europe.
The Company is developing Riquent® (abetimus sodium) for the treatment
of patients with lupus kidney disease, a leading cause of sickness and
death in
lupus patients. The Company is also developing LJP 1082, for
the treatment of antibody-mediated thrombosis, a condition in which patients
can suffer from recurrent stroke,
deep-vein thrombosis, and other thrombotic events. The Company is developing highly
selective inhibitors of semicarbazide-sensitive amine oxidase (SSAO), an enzyme
that has been implicated in inflammatory responses in many tissues and organs.
Toleragens®--
inactivating targeted B cells More
on La Jolla